AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its ...

A collaborative study led by Prof. Liu Guanghui from the Institute of Zoology of the Chinese Academy of Sciences and Dr. Wang ...

AstraZeneca has agreed to acquire Belgian in vivo cell therapy biotech EsoBiotec, strengthening its position in the emerging ...

Lentiviral vectors (LVVs ... has its own peculiarities and associated complexity when compared with other vector types, especially because of the intrinsic characteristics of the vectors ...

There was a dose-dependent, transient increase in serum ALT concentrations using the lentiviral vector not encoding accessory proteins (Fig. 3). In addition, the 8–10×10 8 TU dose of vector was ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

A recent study on T cell gene therapy trials shows that while secondary malignancies occur in a small percentage of patients, ...

A collaborative study led by Prof. LIU Guanghui from the Institute of Zoology of the Chinese Academy of Sciences and Dr. WANG Si from Xuanwu Hospital ...

Oxford Biomedica plc (OTCMKTS:OXBDF – Get Free Report) saw a large increase in short interest in February. As of February 28th, there was short interest totalling 78,300 shares, an increase of 131.0% ...

OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the ...